Cervical Cancer: Study on Molecular Landscape and Protein Biomarkers. Current Diagnostic and Therapeutic Capabilities

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 25 June 2024 | Viewed by 893

Special Issue Editors


E-Mail Website
Guest Editor
1. Division of Histology and Embryology, Department of Human Morphology and Embry-ology, Wroclaw Medical University, Wroclaw, Poland
2. Department of Gynecology and Obstetrics, Poviat Hospital, Olesnica, Poland
Interests: pathomorphology; tumor markers; oncology; gynecology and obstetrics; gynecological oncology; cervical pathology

E-Mail Website
Guest Editor
1. Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland
2. Department of Physiotherapy, Wroclaw University School of Physical Education, Wroclaw, Poland
Interests: pathomorphology; experimental oncology; neoplastic transformation processes; neoplastic process markers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cervical cancer is still the leading gynecologic health problem globally. The association between certain high-risk strains of Human Papilloma Virus (HPV) and cervical cancer is well established. Although HPV is essential to the transformation of cervical epithelial cells, it is not sufficient, and a variety of cofactors and molecular events influence whether cervical cancer will develop. Even though screening programs and vaccine-driven prevention have substantially changed the landscape for cervical cancer, many questions still remain unanswered.

Universal vaccination against HPV is typically the basic initial population procedure. Next in line is properly conducted screening based on sensitive and specific tests. This step is one of the main targets of conducted studies, which focus on seeking new tests or methods or a combination of already known ones. Finally, as we currently try to offer our patients tailored, precise and personalized treatment, researchers search for molecular treatment options as well as markers of prognostic and predictive value.

In our Special Issue, we would like to focus on diagnostic and therapeutic capabilities regarding cervical cancer on the basis of experimental studies as well as review papers showing the state of the art in this field.

Dr. Christopher Kobierzycki
Prof. Dr. Piotr Dzięgiel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cervical cancer
  • cervical dysplasia
  • human papilloma virus (HPV)
  • tumor markers
  • cancerogenesis
  • genotyping

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 2736 KiB  
Article
The Micro-Immunotherapy Medicine 2LPAPI® Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells
by Camille Jacques, Flora Marchand, Mathias Chatelais, Virginie Albinet, Claire Coustal and Ilaria Floris
Cancers 2024, 16(7), 1421; https://doi.org/10.3390/cancers16071421 - 05 Apr 2024
Viewed by 655
Abstract
Human papillomavirus (HPV) is the second most common infectious agent causing cancer. Persistent infection with high-risk (HR)-HPV can lead to cervical intra-epithelial neoplasia and cervical carcinomas (CC). While host immune response is necessary for viral clearance, chronic immune activation contributes to a low-grade [...] Read more.
Human papillomavirus (HPV) is the second most common infectious agent causing cancer. Persistent infection with high-risk (HR)-HPV can lead to cervical intra-epithelial neoplasia and cervical carcinomas (CC). While host immune response is necessary for viral clearance, chronic immune activation contributes to a low-grade inflammation that can ultimately lead to carcinogenesis. The micro-immunotherapy medicine (MIM) 2LPAPI® could be a valuable tool to manage the clearance of the virus and reduce the risk of developing CC. In this in vitro study, we aimed to investigate its mode of action. We showed that actives from the MIM increased the IL-6, IFN-γ, and IP-10 secretion in human peripheral blood mononuclear cells (PBMCs) exposed to peptides derived from the HPV-16 capsid (HPV16(L1)). This could reflect an increase in the immune activity toward HPV-16. At the same time, some active substances reduced the lympho-proliferation and the expression of T-cell activation markers. Finally, some of the MIM actives displayed antiproliferative effects in CC-derived HeLa cells under serum-starvation conditions. Altogether, this body of data highlighted for the first time the dual effect of MIM in the framework of HR-HPV infections as a potential (i) immune modulator of HPV16(L1)-treated PBMCs and (ii) antiproliferative agent of HPV-positive CC cells. Full article
Show Figures

Figure 1

Back to TopTop